中和抗体の世界市場レポート2025年

中和抗体の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.7％で4,011億6,000万米ドルに成長します。このような成長が期待される背景には、新興感染症の増加、自己免疫疾患の増加、抗体ベースの治療パイプラインの拡大、精密医療への需要の高まり、標的治療への関心の高まりなどがあります。予測期間中の主な動向としては、二重特異性抗体や多重特異性抗体へのシフト、抗体探索における人工知能（AI）の活用、抗体薬物複合体の開発、植物由来抗体生産の利用拡大、個別化免疫療法アプローチの台頭などが挙げられます。

感染症の流行の増加は、今後数年間の中和抗体市場の成長を牽引すると予想されます。感染症とは、細菌、ウイルス、真菌、寄生虫などの有害な微生物によって引き起こされる病気で、人から人へ直接的または間接的に感染します。これらの疾病の発生率の増加は、国境を越えた病原体の迅速な伝播を可能にする世界の旅行の増加に大きく起因しています。中和抗体は、病原体を特異的に標的としてブロックすることによって病気の進行を防ぎ、感染症の治療において重要な役割を果たしています。正確かつタイムリーな免疫防御を提供することで、患者の予後改善に貢献します。例えば、2024年2月、英国健康安全保障局は、イングランドにおける結核患者数が2023年には4,850人となり、2022年の4,380人から10.7％増加したと報告しました。これは、感染症の蔓延が中和抗体市場をいかに強化しているかを浮き彫りにしています。

中和抗体市場の主要企業は、ウイルスを直接中和し、ヒト細胞への侵入を阻止することで、より効果的に感染症と闘うために、標的治療を含む先進治療の開発を優先しています。標的治療薬は、がんやウイルス感染など、病気を引き起こす細胞の増殖や生存に不可欠な特定の分子マーカーや経路に作用するように設計されています。例えば、2022年2月、米国の製薬会社イーライリリー・アンド・カンパニーは、COVID-19の治療を目的とした中和モノクローナル抗体療法であるベブテロビマブについて、米国食品医薬品局（FDA）から緊急使用許可（EUA）を取得しました。Bebtelovimabは、入院や死亡を含む重症化への進行リスクが高い軽度から中等度のCOVID-19患者を対象としています。今回の承認は、新たなウイルス変異体が出現する中、タイムリーな治療への取り組みを支援するものであり、これにより、疾患の重症度を軽減し、患者の転帰を向上させる一助となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の中和抗体：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の中和抗体市場：成長率分析
• 世界の中和抗体市場の実績：規模と成長, 2019-2024
• 世界の中和抗体市場の予測：規模と成長, 2024-2029, 2034F
• 世界の中和抗体：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の中和抗体市場抗体の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• ポリクローナル抗体
• 世界の中和抗体市場ターゲットウイルス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• SARS-CoV-2（COVID-19）
• ヒト免疫不全ウイルス（HIV）
• インフルエンザ
• エボラ
• ジカ熱
• C型肝炎
• その他の標的ウイルス
• 世界の中和抗体市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エンドユーザーへの直接販売
• 販売代理店
• オンライン小売
• その他の流通チャネル
• 世界の中和抗体市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治療薬
• 診断
• 研究開発
• 世界の中和抗体市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 調査機関
• 診断検査室
• 製薬会社
• その他のエンドユーザー
• 世界の中和抗体市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 完全ヒトモノクローナル抗体
• ヒト化モノクローナル抗体
• キメラモノクローナル抗体
• マウスモノクローナル抗体
• 世界の中和抗体市場ポリクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 動物由来ポリクローナル抗体
• 組み換えポリクローナル抗体
• ヒトポリクローナル抗体製剤

第7章 地域別・国別分析

• 世界の中和抗体市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の中和抗体市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 中和抗体市場：競合情勢
• 中和抗体市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• GlaxoSmithKline plc
• Eli Lilly and Company
• Regeneron Pharmaceuticals Inc.
• GeNext Genomics
• Celltrion Healthcare Co. Ltd
• BeiGene Ltd
• AbCellera Biologics Inc.
• BMC Pharmacology and Toxicology
• Anthos Therapeutics
• Immunome Inc.
• Sorrento Therapeutics Inc.
• Tonix Pharmaceuticals
• Abwiz Bio
• AXIM Biotechnologies

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 中和抗体市場2029：新たな機会を提供する国
• 中和抗体市場2029：新たな機会を提供するセグメント
• 中和抗体市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A neutralizing antibody is a specific type of antibody that attaches directly to a virus or pathogen, effectively blocking its ability to infect host cells. Its main function is to stop infection by neutralizing the pathogen's harmful effects, thereby halting disease progression.

Neutralizing antibodies primarily come in two forms: monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are lab-engineered molecules tailored to bind to a specific antigen, such as a virus or cancer cell. These antibodies are used to target a range of viruses, including SARS-CoV-2 (COVID-19), HIV, influenza, Ebola, Zika, and hepatitis C, among others. Distribution channels include direct sales to end-users, distributors, online retailers, and other methods. Applications span across therapeutics, diagnostics, and research and development, catering to end-users such as hospitals and clinics, research institutions, diagnostic laboratories, pharmaceutical companies, and others.

The neutralizing antibody market research report is one of a series of new reports from The Business Research Company that provides neutralizing antibody market statistics, including neutralizing antibody industry global market size, regional shares, competitors with a neutralizing antibody market share, detailed neutralizing antibody market segments, market trends and opportunities, and any further data you may need to thrive in the neutralizing antibody industry. This neutralizing antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neutralizing antibody market size has grown rapidly in recent years. It will grow from $230.25 billion in 2024 to $257.81 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. Historical growth has been driven by a rise in biologic drug approvals, increased funding for antibody research, higher prevalence of chronic viral infections, growing awareness of immunotherapy, and expanding healthcare spending.

The neutralizing antibody market size is expected to see rapid growth in the next few years. It will grow to $401.16 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. This expected growth will be fueled by a rise in emerging infectious diseases, increasing autoimmune disorders, expansion of antibody-based therapy pipelines, growing demand for precision medicine, and increased interest in targeted therapies. Key trends over the forecast period include a shift toward bispecific and multispecific antibodies, the use of artificial intelligence (AI) in antibody discovery, the development of antibody-drug conjugates, increased use of plant-based antibody production, and a rise in personalized immunotherapy approaches.

The increasing prevalence of infectious diseases is anticipated to drive the growth of the neutralizing antibody market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread from one person to another either directly or indirectly. The growing incidence of these diseases is largely attributed to the rise in global travel, which enables the rapid transmission of pathogens across borders. Neutralizing antibodies play a crucial role in treating infectious diseases by specifically targeting and blocking pathogens, thereby preventing the progression of illness. They contribute to improved patient outcomes by offering precise and timely immune protection. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased to 4,850 in 2023, up by 10.7% from 4,380 cases in 2022. This highlights how the rising prevalence of infectious diseases is bolstering the neutralizing antibody market.

Leading companies in the neutralizing antibody market are prioritizing the development of advanced therapies, including targeted treatments, to more effectively combat infectious diseases by directly neutralizing viruses and preventing their entry into human cells. Targeted therapies are designed to act on specific molecular markers or pathways that are essential for the growth and survival of disease-causing cells, such as those involved in cancers or viral infections. For instance, in February 2022, Eli Lilly and Company, a U.S.-based pharmaceutical firm, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Bebtelovimab, a neutralizing monoclonal antibody therapy aimed at treating COVID-19. Bebtelovimab is intended for use in patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death. This approval supports timely treatment efforts amid the emergence of new viral variants, thereby aiding in the reduction of disease severity and enhancement of patient outcomes.

In July 2022, Brii Biosciences Limited, a biotechnology firm based in China, collaborated with China Resources Pharmaceutical Commercial Group Co., Ltd. through its joint venture, TSB Therapeutics (Beijing) Co. Ltd., to support the commercialization of amubarvimab/romlusevimab in China. This partnership is focused on expanding access to the treatment for patients with mild to moderate COVID-19 who are at risk of developing severe illness, and accelerating its availability across the country. China Resources Pharmaceutical Commercial Group Co., Ltd. is engaged in the distribution of neutralizing antibody products within China.

Major players in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, and AXIM Biotechnologies.

North America was the largest region in the neutralizing antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neutralizing antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neutralizing antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neutralizing antibody market consists of sales of antibody kits, reagents, and related diagnostic and therapeutic products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in usd, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neutralizing Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neutralizing antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neutralizing antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neutralizing antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Antibody Type: Monoclonal Antibodies; Polyclonal Antibodies
• 2) By Target Virus: SARS-CoV-2 (COVID-19); Human Immunodeficiency Viruses (HIV); Influenza; Ebola; Zika; Hepatitis C; Other Target Viruses
• 3) By Distribution Channel: Direct Sales To End-Users; Distributors; Online Retail; Other Distribution Channels
• 4) By Application: Therapeutics; Diagnostics; Research And Development
• 5) By End User: Hospitals And Clinics; Research Institutes; Diagnostic Laboratories; Pharmaceutical Companies; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
• 2) By Polyclonal Antibodies: Animal-Derived Polyclonal Antibodies; Recombinant Polyclonal Antibodies; Human Polyclonal Antibody Preparations
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neutralizing Antibody Market Characteristics

3. Neutralizing Antibody Market Trends And Strategies

4. Neutralizing Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neutralizing Antibody Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neutralizing Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neutralizing Antibody Market Growth Rate Analysis
• 5.4. Global Neutralizing Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neutralizing Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neutralizing Antibody Total Addressable Market (TAM)

6. Neutralizing Antibody Market Segmentation

• 6.1. Global Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Polyclonal Antibodies
• 6.2. Global Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• SARS-CoV-2 (COVID-19)
• Human Immunodeficiency Viruses (HIV)
• Influenza
• Ebola
• Zika
• Hepatitis C
• Other Target Viruses
• 6.3. Global Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sales To End-Users
• Distributors
• Online Retail
• Other Distribution Channels
• 6.4. Global Neutralizing Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapeutics
• Diagnostics
• Research And Development
• 6.5. Global Neutralizing Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Research Institutes
• Diagnostic Laboratories
• Pharmaceutical Companies
• Other End Users
• 6.6. Global Neutralizing Antibody Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fully Human Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Chimeric Monoclonal Antibodies
• Murine Monoclonal Antibodies
• 6.7. Global Neutralizing Antibody Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Animal-Derived Polyclonal Antibodies
• Recombinant Polyclonal Antibodies
• Human Polyclonal Antibody Preparations

7. Neutralizing Antibody Market Regional And Country Analysis

• 7.1. Global Neutralizing Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neutralizing Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neutralizing Antibody Market

• 8.1. Asia-Pacific Neutralizing Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neutralizing Antibody Market

• 9.1. China Neutralizing Antibody Market Overview
• 9.2. China Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neutralizing Antibody Market

• 10.1. India Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neutralizing Antibody Market

• 11.1. Japan Neutralizing Antibody Market Overview
• 11.2. Japan Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neutralizing Antibody Market

• 12.1. Australia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neutralizing Antibody Market

• 13.1. Indonesia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neutralizing Antibody Market

• 14.1. South Korea Neutralizing Antibody Market Overview
• 14.2. South Korea Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neutralizing Antibody Market

• 15.1. Western Europe Neutralizing Antibody Market Overview
• 15.2. Western Europe Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neutralizing Antibody Market

• 16.1. UK Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neutralizing Antibody Market

• 17.1. Germany Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neutralizing Antibody Market

• 18.1. France Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neutralizing Antibody Market

• 19.1. Italy Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neutralizing Antibody Market

• 20.1. Spain Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neutralizing Antibody Market

• 21.1. Eastern Europe Neutralizing Antibody Market Overview
• 21.2. Eastern Europe Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neutralizing Antibody Market

• 22.1. Russia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neutralizing Antibody Market

• 23.1. North America Neutralizing Antibody Market Overview
• 23.2. North America Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neutralizing Antibody Market

• 24.1. USA Neutralizing Antibody Market Overview
• 24.2. USA Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neutralizing Antibody Market

• 25.1. Canada Neutralizing Antibody Market Overview
• 25.2. Canada Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neutralizing Antibody Market

• 26.1. South America Neutralizing Antibody Market Overview
• 26.2. South America Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neutralizing Antibody Market

• 27.1. Brazil Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neutralizing Antibody Market

• 28.1. Middle East Neutralizing Antibody Market Overview
• 28.2. Middle East Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neutralizing Antibody Market

• 29.1. Africa Neutralizing Antibody Market Overview
• 29.2. Africa Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neutralizing Antibody Market Competitive Landscape And Company Profiles

• 30.1. Neutralizing Antibody Market Competitive Landscape
• 30.2. Neutralizing Antibody Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Neutralizing Antibody Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. GlaxoSmithKline plc
• 31.3. Eli Lilly and Company
• 31.4. Regeneron Pharmaceuticals Inc.
• 31.5. GeNext Genomics
• 31.6. Celltrion Healthcare Co. Ltd
• 31.7. BeiGene Ltd
• 31.8. AbCellera Biologics Inc.
• 31.9. BMC Pharmacology and Toxicology
• 31.10. Anthos Therapeutics
• 31.11. Immunome Inc.
• 31.12. Sorrento Therapeutics Inc.
• 31.13. Tonix Pharmaceuticals
• 31.14. Abwiz Bio
• 31.15. AXIM Biotechnologies

32. Global Neutralizing Antibody Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neutralizing Antibody Market

34. Recent Developments In The Neutralizing Antibody Market

35. Neutralizing Antibody Market High Potential Countries, Segments and Strategies

• 35.1 Neutralizing Antibody Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neutralizing Antibody Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neutralizing Antibody Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer